Cargando…

The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR)

Background Endovascular aneurysm repair (EVAR) has become the treatment modality of choice in patients with abdominal aortic aneurysms. This has resulted in endograft utilization within instructions for use (IFU) and in cases with proximal neck anatomy outside of IFU. Purpose To identify whether gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Barry, Ian P, Turley, Luke P, Mwipatayi, Daniela L, Thomas, Angel, Mwipatayi, Mariah T, Mwipatayi, Bibombe P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095383/
https://www.ncbi.nlm.nih.gov/pubmed/33959465
http://dx.doi.org/10.7759/cureus.14841
_version_ 1783688066614951936
author Barry, Ian P
Turley, Luke P
Mwipatayi, Daniela L
Thomas, Angel
Mwipatayi, Mariah T
Mwipatayi, Bibombe P
author_facet Barry, Ian P
Turley, Luke P
Mwipatayi, Daniela L
Thomas, Angel
Mwipatayi, Mariah T
Mwipatayi, Bibombe P
author_sort Barry, Ian P
collection PubMed
description Background Endovascular aneurysm repair (EVAR) has become the treatment modality of choice in patients with abdominal aortic aneurysms. This has resulted in endograft utilization within instructions for use (IFU) and in cases with proximal neck anatomy outside of IFU. Purpose To identify whether graft selection influences outcomes following EVAR outside of IFU. Methodology A retrospective analysis was conducted from previously published data for 636 patients, collated from the Endurant Stent Graft Natural Selection Global Post-Market Registry (ENGAGE) and the Global Registry for Endovascular Aortic Treatment (GREAT). Patients were recruited into the ENGAGE registry between 2009 and 2011 and into the GREAT registry between August 2010 and October 2016. In ENGAGE, they received the Medtronic Endurant stent graft (Medtronic Vascular Inc, Dublin, Ireland) for infrarenal AAA repair while patients analyzed in GREAT received the Gore Excluder stent-graft (W. L. Gore & Associates, Flagstaff, Arizona). Analyses were performed to evaluate all-cause mortality, aneurysm-related mortality, endoleak occurrence, and surgical reintervention rates between the two cohorts. Results Of the 636 patients, 225 were from ENGAGE (mean age 73 years) and 411 were from GREAT (mean age 75 years). 17.8% were treated outside of IFU in the ENGAGE registry, while 12.4% were treated outside IFU in the GREAT cohort. Five-year freedom from all-cause mortality was similar in both cohorts (65.6% vs. 63.8%). The rate of type IA endoleak development was lower in the Excluder cohort, although this may have been impacted by the fact that only endoleaks that underwent reintervention were recorded within GREAT analysis (Endurant 10.6% vs. Excluder 7.0%). The reintervention rate was 16% at five years following the Endurant aortic graft while it was 13.3% at five years with the Excluder. Conclusion Treatment outside of IFU, be it with a suprarenal or an infrarenal fixation device, is associated with worse outcomes. This analysis reinforces the importance of the consideration of either fenestrated or open repair in those aneurysms that fail to satisfy IFU while endovascular repair in such a setting should be reserved as a last resort strategy.
format Online
Article
Text
id pubmed-8095383
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-80953832021-05-05 The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR) Barry, Ian P Turley, Luke P Mwipatayi, Daniela L Thomas, Angel Mwipatayi, Mariah T Mwipatayi, Bibombe P Cureus Cardiac/Thoracic/Vascular Surgery Background Endovascular aneurysm repair (EVAR) has become the treatment modality of choice in patients with abdominal aortic aneurysms. This has resulted in endograft utilization within instructions for use (IFU) and in cases with proximal neck anatomy outside of IFU. Purpose To identify whether graft selection influences outcomes following EVAR outside of IFU. Methodology A retrospective analysis was conducted from previously published data for 636 patients, collated from the Endurant Stent Graft Natural Selection Global Post-Market Registry (ENGAGE) and the Global Registry for Endovascular Aortic Treatment (GREAT). Patients were recruited into the ENGAGE registry between 2009 and 2011 and into the GREAT registry between August 2010 and October 2016. In ENGAGE, they received the Medtronic Endurant stent graft (Medtronic Vascular Inc, Dublin, Ireland) for infrarenal AAA repair while patients analyzed in GREAT received the Gore Excluder stent-graft (W. L. Gore & Associates, Flagstaff, Arizona). Analyses were performed to evaluate all-cause mortality, aneurysm-related mortality, endoleak occurrence, and surgical reintervention rates between the two cohorts. Results Of the 636 patients, 225 were from ENGAGE (mean age 73 years) and 411 were from GREAT (mean age 75 years). 17.8% were treated outside of IFU in the ENGAGE registry, while 12.4% were treated outside IFU in the GREAT cohort. Five-year freedom from all-cause mortality was similar in both cohorts (65.6% vs. 63.8%). The rate of type IA endoleak development was lower in the Excluder cohort, although this may have been impacted by the fact that only endoleaks that underwent reintervention were recorded within GREAT analysis (Endurant 10.6% vs. Excluder 7.0%). The reintervention rate was 16% at five years following the Endurant aortic graft while it was 13.3% at five years with the Excluder. Conclusion Treatment outside of IFU, be it with a suprarenal or an infrarenal fixation device, is associated with worse outcomes. This analysis reinforces the importance of the consideration of either fenestrated or open repair in those aneurysms that fail to satisfy IFU while endovascular repair in such a setting should be reserved as a last resort strategy. Cureus 2021-05-04 /pmc/articles/PMC8095383/ /pubmed/33959465 http://dx.doi.org/10.7759/cureus.14841 Text en Copyright © 2021, Barry et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiac/Thoracic/Vascular Surgery
Barry, Ian P
Turley, Luke P
Mwipatayi, Daniela L
Thomas, Angel
Mwipatayi, Mariah T
Mwipatayi, Bibombe P
The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
title The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
title_full The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
title_fullStr The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
title_full_unstemmed The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
title_short The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
title_sort impact of endograft selection on outcomes following treatment outside of instructions for use (ifu) in endovascular abdominal aortic aneurysm repair (evar)
topic Cardiac/Thoracic/Vascular Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095383/
https://www.ncbi.nlm.nih.gov/pubmed/33959465
http://dx.doi.org/10.7759/cureus.14841
work_keys_str_mv AT barryianp theimpactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT turleylukep theimpactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT mwipatayidanielal theimpactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT thomasangel theimpactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT mwipatayimariaht theimpactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT mwipatayibibombep theimpactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT barryianp impactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT turleylukep impactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT mwipatayidanielal impactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT thomasangel impactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT mwipatayimariaht impactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar
AT mwipatayibibombep impactofendograftselectiononoutcomesfollowingtreatmentoutsideofinstructionsforuseifuinendovascularabdominalaorticaneurysmrepairevar